(NASDAQ: NYXH) Nyxoah Sa's forecast annual revenue growth rate of 152.39% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.78%, and it is also forecast to beat the US market's average forecast revenue growth rate of 8.83%.
Nyxoah Sa's revenue in 2024 is $5,464,516.On average, 4 Wall Street analysts forecast NYXH's revenue for 2024 to be $198,665,340, with the lowest NYXH revenue forecast at $183,981,230, and the highest NYXH revenue forecast at $208,741,321. On average, 4 Wall Street analysts forecast NYXH's revenue for 2025 to be $1,063,892,957, with the lowest NYXH revenue forecast at $796,105,697, and the highest NYXH revenue forecast at $1,373,497,259.
In 2026, NYXH is forecast to generate $3,312,349,925 in revenue, with the lowest revenue forecast at $2,408,606,611 and the highest revenue forecast at $4,273,522,894.